Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook

anlotinib

  • Open Access
    Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial
    Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han and Kai Li
    Cancer Biology & Medicine October 2024, 21 (10) 951-962; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0423
  • Open Access
    Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial
    Shuzhen Lai, Peijing Li, Xiaohui Liu, Guihong Liu, Tieming Xie, Xing Zhang, Xiaoxuan Wang, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Fangxiao Lu, Lei Wang, Fagui Jiang, Caixing Sun, Yuanyuan Chen and Ming Chen
    Cancer Biology & Medicine May 2024, 21 (5) 433-444; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0373
  • You have access
    Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
    Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng and Kai Li
    Cancer Biology & Medicine August 2022, 19 (8) 1249-1258; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0727
  • You have access
    Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
    Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu and Peng Yuan
    Cancer Biology & Medicine August 2021, 18 (3) 849-859; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0463
  • You have access
    The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
    Yan Song, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Jie He and Jing Huang
    Cancer Biology & Medicine May 2021, 18 (2) 562-568; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0187
  • You have access
    Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
    Tingting Qin, Zhujun Liu, Jing Wang, Junling Xia, Shaochuan Liu, Yanan Jia, Hailin Liu and Kai Li
    Cancer Biology & Medicine August 2020, 17 (3) 753-767; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0024
  • You have access
    Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
    Xiaoling Zhang, Yan Zhang, Yanan Jia, Tingting Qin, Cuicui Zhang, Yueya Li, Chengmou Huang, Zhujun Liu, Jing Wang and Kai Li
    Cancer Biology & Medicine May 2020, 17 (2) 418-432; DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0215
  • You have access
    Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
    Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhujun Liu, Baohui Han and Kai Li
    Cancer Biology & Medicine November 2018, 15 (4) 443-451; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0158

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2025 Cancer Biology & Medicine

Powered by HighWire